Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort

Infection

Volumn 42, Issue 6, 2014, Pages 991-997

  Leistner, R ^a   Gurntke S ^a   Sakellariou, C ^a   Denkel, L A ^a   Bloch, A ^a   Gastmeier, P ^a   Schwab, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bloodstream infection; Cost analysis; Costs; Extended spectrum beta lactamase; K. pneumoniae; Length of stay

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

AGED; ANTIBIOTIC RESISTANCE; BACTEREMIA; BIOSYNTHESIS; COHORT ANALYSIS; COST OF ILLNESS; CROSS INFECTION; DRUG EFFECTS; ECONOMICS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; HUMAN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; COHORT STUDIES; COST OF ILLNESS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84939877271     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0670-9     Document Type: Article

References (18)

1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC. 2013.
2. Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis. 2012;25:371–7.
3. Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011;39:599–601.
4. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.
5. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by E. coli and influence of extended-spectrum-beta-lactamase positivity and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.
6. Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-positive Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34:133–43.
7. Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β-lactamase positivity in cases of E. coli bloodstream infection. J Glob Antimicrob Resist. 2014.
8. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–62.
9. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012;55:967–75.
10. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-positive Enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–11.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
12. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
13. Clinical and Laboratorical Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratorical Standards Institute (CLSI), Wayne, PA, USA [serial on the Internet]. 2012; Twenty-second Informational Supplement M100–S22.
14. Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) positive bacteria in China. Curr Med Res Opin. 2010;26:1443–9.
15. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-positive E. coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.
16. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to E. coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66:398–407.
17. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase positivity in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.
18. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase positive Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014.